Corcept Therapeutics (CORT) Free Cash Flow (2010 - 2026)
Corcept Therapeutics (CORT) posted Free Cash Flow of $31.0 million for Q2 2026, up 282.73% sequentially from -$17.0 million in Q1 2026, and down 29.89% YoY from $44.2 million in Q2 2025.
Corcept Therapeutics (CORT) Free Cash Flow (2010 - 2026) Analysis & Trends
Corcept Therapeutics has reported Free Cash Flow for 17 years, with the latest figure at $31.0 million in Q2 2026.
- Quarterly Free Cash Flow fell 29.89% year-over-year to $31.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $106.9 million (down 40.76% YoY) and the FY2025 annual result came in at $141.8 million, down 27.71% from the prior year.
- Free Cash Flow climbed to $31.0 million in Q2 2026 per CORT's latest filing, from -$17.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $71.7 million in Q3 2024 and troughed at -$17.0 million in Q1 2026.
- A 5-year average of $33.2 million and a median of $34.3 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2026: Free Cash Flow jumped 984.05% in 2024, then tumbled 463.76% in 2026.
- Over 5 years, Free Cash Flow stood at $33.4 million in 2022, then plunged by 83.42% to $5.5 million in 2023, then surged by 984.05% to $59.9 million in 2024, then plunged by 35.94% to $38.4 million in 2025, then slipped by 19.23% to $31.0 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered $31.0 million, -$17.0 million, and $38.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 31.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.02 Mn |
| Jun 30, 2026 | 31.02 Mn |
| Mar 31, 2026 | -16.97 Mn |
| Mar 31, 2026 | -16.97 Mn |
| Dec 31, 2025 | 38.40 Mn |
| Dec 31, 2025 | 38.40 Mn |
| Sep 30, 2025 | 54.48 Mn |
| Sep 30, 2025 | 54.48 Mn |
| Jun 30, 2025 | 44.24 Mn |
| Jun 30, 2025 | 44.24 Mn |
| Mar 31, 2025 | 4.67 Mn |
| Mar 31, 2025 | 4.67 Mn |
| Dec 31, 2024 | 59.94 Mn |
| Dec 31, 2024 | 59.94 Mn |
| Sep 30, 2024 | 71.66 Mn |
| Sep 30, 2024 | 71.66 Mn |
| Jun 30, 2024 | 40.77 Mn |
| Jun 30, 2024 | 40.77 Mn |
| Mar 31, 2024 | 23.76 Mn |
| Mar 31, 2024 | 23.76 Mn |